TNGX News and Press, Tango Therapeutics Inc. From 03/06/23

BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective March 1, 2023, the Compensation Committee of T...

BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced the appointment of Adam Crystal, M.D., Ph.D. as President of Researc...

Summary Tango Therapeutics' SPAC entry to the market and Gilead deal has put a large dollar figure besides its name. Tango has an upcoming proof of concept data readout that should validate its platform. The science is interesting, they have solid cash, so Tango Therapeutics may be ...

BOSTON, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Inve...

NEW YORK and VIENNA, Austria, Dec. 15, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today the promotion of Katia Schlienger, M.D., Ph.D., to Chie...

Summary Shares of early clinical-stage biotech Tango Therapeutics, Inc. are down ~50% since going public in August 2021 – primarily victimized by a lack of catalysts and a tough market. However, the shares have rallied strongly over the past month. Tango Therapeutics&#x...

Tango Therapeutics press release ( NASDAQ: TNGX ): Q3 GAAP EPS of -$0.33 misses by $0.01 . Revenue of $6.92M (+1.9% Y/Y) beats by $1.28M . For further details see: Tango Therapeutics GAAP EPS of -$0.33 misses by $0.01, revenue of $6.92M beats by $1.28M

– Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in France – – TNG260 disclosed as a first-in-class CoREST complex inhibitor for treatment of STK11-mut...

Shares of Tango Therapeutics (NASDAQ: TNGX) , a biotech company that specializes in target cancer therapies, rose 39.7% this week, according to data from S&P Global Intelligence . The stock closed at $5.17 last Friday, then opened at $5.34 on Monday. Its shares climbed throu...

H.C. Wainwright has started Tango Therapeutics ( NASDAQ: TNGX ) with a buy rating citing its use of synthetic lethality to develop cancer candidates. The firm has a $10 price target (~43% upside based on Wednesday's close). Analyst Robert Burns said that the targets th...